Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

REMAIN-1 Midpoint Cohort 6-month Results

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Mar 17, 2026

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Feb 26, 2026

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

Jan 29, 2026

Events

Fractyl Health 4Q 2025 Financial Results and Business Update Conference Call

Mar 24, 2026 | 4:30 PM EDT

REMAIN-1 Midpoint Cohort 6-month Randomized Results Conference Call

Jan 29, 2026 | 8:00 AM EST

SEC Filings

Report of unscheduled material events or corporate event

Mar 17, 2026 | Form Type: 8-K

Mar 17, 2026

Report of unscheduled material events or corporate event

Feb 26, 2026 | Form Type: 8-K

Feb 26, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200